Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Carcinoma 1

Interventions

Radiosurgery 8Docetaxel 4Cisplatin 4Carboplatin 4Magnetic Resonance Spectroscopy 3Filgrastim 3pembrolizumab 2Specimen Handling 2Radiotherapy 2Paclitaxel 2Nivolumab 2Mental Status and Dementia Tests 2Memantine 2Fluorodeoxyglucose F18 2Etoposide 2temsirolimus 1sargramostim 1sacituzumab govitecan 1regorafenib 1pentetreotide 1pazopanib 1molibresib 1etoposide phosphate 1etirinotecan pegol 1entinostat 1durvalumab 1cc-486 1budigalimab 1berzosertib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × molibresib × CNS × Clear all
NCT01587703 2020-03-16

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

GlaxoSmithKline

Phase 1 Completed
196 enrolled 78 charts
CNSPlasma cellThoracic

Carcinoma, Multiple Myeloma, Neoplasms, Neuroblastoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡